KYMR today
$127.57+$0.40 (+0.31%)close Nov 13, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bearish
1 hourDescending Triangle
15 minStrong Bearish
5 minConsolidating
Daily trend turns down below $99.52
Key levels
Resistance$142.92
Resistance$127.74
Support$117.31
Support$109.05
Latest news & SEC filings
AnalystBarclays keeps Overweight on Kymera Therapeutics, lifts price target
AnalystBarclays keeps Overweight rating on Kymera Therapeutics, lifts target to $170
AnalystTruist Securities keeps Buy rating on Kymera Therapeutics, lifts target to $150
All KYMR news →About Kymera Therapeutics
Kymera Therapeutics is a biopharmaceutical company in the clinic stage that creates pills taken by mouth which use the body's own protein disposal machinery to remove proteins that cause illness. Its pipeline focuses on immune and inflammatory conditions, with drug candidates aimed at targets known as STAT6, IRF5, and IRAK4, including KT-621 for skin and lung inflammatory diseases. It works with partners such as Sanofi and Gilead on additional programs. The company is based in the United States.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
Kymera Therapeutics, Inc. (KYMR)
What Is the Price Target for KYMR?
SEPT Low Target
$116.00
SEPT Mid Target
$146.00
SEPT High Target
$170.00
Analyst Consensus
$146.00
Is KYMR a Buy or Sell Right Now?
Thesis
- •Revenue growing -16.7% YoY with SLOWING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for KYMR.
Start Free Trial →Is KYMR Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$120.03
16
Moat Score
NONE
4/9
Piotroski Score
38.5
Altman Z-Score
What Is Smart Money Doing with KYMR?
Insider Signal
SELLING
0 buys / 16 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Mainolfi Nello | director officer | Buy | 30,000 | $62K | Oct 1, 2026 |
| Mainolfi Nello | director officer | Sale | 3,525 | $393K | Oct 1, 2026 |
| Mainolfi Nello | director officer | Sale | 5,506 | $619K | Oct 1, 2026 |
| Mainolfi Nello | director officer | Sale | 4,876 | $552K | Oct 1, 2026 |
| Mainolfi Nello | director officer | Sale | 7,601 | $870K | Oct 1, 2026 |
| Mainolfi Nello | director officer | Sale | 8,230 | $950K | Oct 1, 2026 |
| Mainolfi Nello | director officer | Sale | 262 | $30K | Oct 1, 2026 |
| Adams Brian | officer | Sale | 1,209 | $140K | Sep 4, 2026 |
| Adams Brian | officer | Sale | 3,025 | $353K | Sep 4, 2026 |
| Adams Brian | officer | Sale | 2,137 | $251K | Sep 4, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →KYMR Growth Story
Revenue YoY
-16.7%
3yr Revenue CAGR
-5.7%
EPS Growth YoY
-23.83%
FCF Growth YoY
-13.0%
Revenue Trend
SLOWING
Dark Pool Trades for KYMR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for KYMR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:07 | $127.57 | 5,285 | $$674K | BUY |
| 21:00:07 | $127.57 | 22,405 | $$2.9M | BUY |
| 20:45:24 | $127.94 | 1,945 | $$249K | SELL |
| 19:32:00 | $128.45 | 2,397 | $$308K | SELL |
| 18:18:31 | $128.99 | 1,975 | $$255K | BUY |
5 dark pool trades shown · $$4.3M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for KYMR
PREVIEWSEPT Investing provides real-time options flow tracking for KYMR, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $135 | Dec 18 | 35 | $$5614 | 2 | SWEEP |
| CALL | $135 | Dec 18 | 35 | $$5614 | 2 | SWEEP |
| CALL | $135 | Dec 18 | 35 | $$5618 | 2 | SWEEP |
| CALL | $135 | Dec 18 | 35 | $$2811 | 1 | SWEEP |
| CALL | $135 | Dec 18 | 35 | $$2810 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About KYMR
4 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for KYMR. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Smart Money Moves $LITE — Wupen Yuen | Sale $430K $XOS — OSTERMANN DIETMAR | Sale $15K $ATRA — Cherry Brian N | Sale $1000K $KYMR — Adams Brian | Sale $140K $KYMR — Adams Brian | Sale $353K
Smart Money Moves $LITE — Wupen Yuen | Sale $430K $XOS — OSTERMANN DIETMAR | Sale $15K $ATRA — Cherry Brian N | Sale $1000K $KYMR — Adams Brian | Sale $140K $KYMR — Adams Brian | Sale $353K
Smart Money Moves $LITE — Wupen Yuen | Sale $430K $XOS — OSTERMANN DIETMAR | Sale $15K $ATRA — Cherry Brian N | Sale $1000K $KYMR — Adams Brian | Sale $140K $KYMR — Adams Brian | Sale $353K
Join 3,500+ traders discussing KYMR in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Kymera Therapeutics, Inc. (KYMR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →KYMR — frequently asked questions
What is KYMR stock price today?
Kymera Therapeutics, Inc. (KYMR) is at $127.57, up 0.31% (+$0.40) at the Nov 13, 2026 close.
Why is KYMR stock moving today?
Latest KYMR news — Nov 2, 2026: Barclays keeps Overweight on Kymera Therapeutics, lifts price target · Nov 2, 2026: Barclays keeps Overweight rating on Kymera Therapeutics, lifts target to $170
What is the KYMR price target?
The average analyst price target for KYMR is $146.00, ranging from $116 to $170, based on 15 analysts. Latest: Barclays maintains on Nov 2, 2026.
What do analysts rate KYMR?
Analyst ratings for KYMR: 1 Buy, 21 Hold, 2 Sell — consensus Hold.
Did KYMR beat earnings?
KYMR last reported on Oct 29, 2026: EPS -$1.32 vs -$1.26 expected — a miss of 4.8%.
Does KYMR pay a dividend?
KYMR does not currently pay a dividend.
What are KYMR support and resistance levels?
Support: $117.31, $109.05, $101.75. Resistance: $127.74, $142.92.
What are insiders doing with KYMR?
Insider activity: SELLING, 0 buys and 16 sells in the last 90 days.
What is the latest news on KYMR?
Nov 2, 2026: Barclays keeps Overweight on Kymera Therapeutics, lifts price target · Nov 2, 2026: Barclays keeps Overweight rating on Kymera Therapeutics, lifts target to $170 · Oct 30, 2026: Truist Securities keeps Buy rating on Kymera Therapeutics, lifts target to $150